Aytu BioPharma (NASDAQ:AYTU) Stock Rating Cut to Hold at Lake Street Capital

Aytu BioPharma (NASDAQ:AYTU – Get Free Report) was downgraded by stock analysts at Lake Street Capital from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. They presently have a $2.70 price objective on the stock. Lake Street Capital‘s price target would indicate a potential upside of 48.35% from the stock’s previous close.

AYTU has been the topic of several other research reports. Citigroup reiterated a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday, September 22nd. Weiss Ratings cut Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, October 6th. Finally, Zacks Research downgraded Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research note on Monday, October 5th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.60.

Check Out Our Latest Report on AYTU

Aytu BioPharma Stock Up 2.2%

Shares of NASDAQ:AYTU opened at $1.82 on Tuesday. The company has a market cap of $19.78 million, a price-to-earnings ratio of -1.10 and a beta of 0.24. The firm’s 50-day simple moving average is $2.01 and its 200-day simple moving average is $2.27. The company has a quick ratio of 1.00, a current ratio of 1.13 and a debt-to-equity ratio of 0.26. Aytu BioPharma has a fifty-two week low of $1.75 and a fifty-two week high of $3.06.

Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last issued its quarterly earnings results on Monday, November 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.06. The business had revenue of $14.84 million for the quarter, compared to analyst estimates of $13.27 million. Aytu BioPharma had a negative net margin of 24.76% and a negative return on equity of 56.54%. As a group, equities research analysts predict that Aytu BioPharma will post -0.16 earnings per share for the current year.

Hedge Funds Weigh In On Aytu BioPharma

A number of large investors have recently made changes to their positions in AYTU. Nantahala Capital Management LLC acquired a new stake in shares of Aytu BioPharma in the 2nd quarter worth approximately $2,336,646. Stonepine Capital Management LLC acquired a new position in Aytu BioPharma during the second quarter worth $1,962,780. AWM Investment Company Inc. acquired a new position in Aytu BioPharma during the second quarter worth $1,332,000. Crown Advisors Management Inc. purchased a new stake in Aytu BioPharma during the second quarter worth $430,000. Finally, Arete Wealth Advisors LLC purchased a new stake in Aytu BioPharma during the first quarter worth $135,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.

Aytu BioPharma News Roundup

Here’s some of the latest news about AYTU:

  • Positive Sentiment: Rosemont agreed to acquire Aytu in an all-cash tender offer valued at $2.70 per share. The agreed price gives investors a defined cash consideration if the transaction closes, and Rosemont says the deal will support its U.S. expansion. Completion remains subject to the agreement’s conditions. Rosemont acquisition announcement
  • Positive Sentiment: Fiscal 2027 first-quarter revenue was $14.84 million, above analysts’ $13.27 million estimate, providing a favorable operating result alongside the acquisition news. Aytu quarterly results
  • Neutral Sentiment: Quarterly results were mixed: Aytu reported a loss of $0.20 per share, compared with a $0.08 loss a year earlier. Fiscal 2027 first-quarter results

Aytu BioPharma Company Profile

(Get Free Report)

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.

Featured Stories

Analyst Recommendations for Aytu BioPharma (NASDAQ:AYTU)

Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.